ClearNote Health’s VP Translational Research & Head of Biopharma Development, Gulfem D. Guler, is attending the American Society of Clinical Oncology (ASCO) GU25 Symposium, February 13-15, San Francisco.

Connect with Gulfem to learn more about ClearNote Health’s Virtuoso Epigenomics Platform. Virtuoso leverages 5hmC epigenomic profiling to uncover active cancer biology patterns from cfDNA in plasma, empowering more efficient oncology drug discovery and development.

ClearNote Health
Privacy Overview

We use cookies, subject to your consent, to analyze the use of our website and to ensure you get the best experience. Third parties with whom we collaborate can also install cookies in order to show you personalized advertisements on other websites. Read our cookie policy for more information.
Read our privacy policy to understand how ClearNote Health handles personal information that we collect through our digital properties that link to this Privacy Policy, including our website and other activities described in the privacy policy.